Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing therapies to treat rare and prevalent diseases. Using its proprietary OPERA platform, it designs oligonucleotides to recruit endogenous ADAR enzymes for precise, transient RNA modifications. Its focus includes gene repair, protein modulation, and addressing undruggable targets, with a pipeline targeting conditions like alpha-1 antitrypsin deficiency, leveraging established delivery methods and aiming for disease-modifying, safe, and scalable genetic medicines.
This description was generated via AI from an annual report. Updated about 1 year ago.